Exposure–safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug‐resistant tuberculosis-Reference-Cited by-同舟云学术

Exposure–safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug‐resistant tuberculosis

Published:2021-10-22 Issue:12 Volume:10 Page:1538-1549
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacom & Syst Pharma

Author:

Tanneau Lénaïg¹,Svensson Elin M.¹²,Rossenu Stefaan³,Karlsson Mats O.¹

Affiliation:

1. Department of Pharmacy Uppsala University Uppsala Sweden

2. Department of Pharmacy Radboud Institute for Health Sciences Radboud University Medical Center Nijmegen the Netherlands

3. Department Clinical Pharmacology and Pharmacometrics Janssen Pharmaceutica NV Beerse Belgium

Funder

Vetenskapsrådet

Publisher

Wiley

Subject

Pharmacology (medical),Modeling and Simulation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12722

Reference35 articles.

1. World Health Organization.WHO Global tuberculosis report 2020. Published2020. Accessed October 11 2021.https://www.who.int/publications/i/item/9789240013131

2. World Health Organization.WHO consolidated guidelines on tuberculosis module 4: treatment ‐ drug‐resistant tuberculosis treatment. Accessed October 12 2021.https://www.who.int/publications‐detail‐redirect/9789240007048

3. Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis

4. Compassionate use of delamanid in combination with bedaquiline for the treatment of multidrug-resistant tuberculosis

5. Modelling of mycobacterial load reveals bedaquiline’s exposure–response relationship in patients with drug-resistant TB

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Second-line antituberculosis drug exposure thresholds predictive of adverse events in multidrug-resistant tuberculosis treatment;International Journal of Infectious Diseases;2024-03

2. Clinical considerations and pharmacokinetic interactions between HIV and tuberculosis therapeutics;Expert Review of Clinical Pharmacology;2024-02-14

3. Clinical research progress of novel antituberculosis drugs on multidrug-resistant tuberculosis;Postgraduate Medical Journal;2024-01-10

4. Effect of Bedaquiline and Delamanid Pharmacokinetics on Sputum Culture Conversion and Adverse Events in Drug-Resistant Tuberculosis;Therapeutic Drug Monitoring;2024-01-01

5. The effect of anti-tuberculosis drug pharmacokinetics on QTc prolongation;International Journal of Antimicrobial Agents;2023-10